Evidence map›Paper›PMID 29594912›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2018

Long-Term Oncologic Outcomes of Minimally Invasive Proctectomy for Rectal Adenocarcinoma.

Amit Merchea, Shahzad M Ali, Scott R Kelley, Emilie Duchalais, Jasim Y Alabbad, Eric J Dozois, David W Larson

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Amit MercheaDivision of Colon and Rectal Surgery, Mayo Clinic, Jacksonville, FL, 32224, USA. merchea.amit@mayo.edu.ORCID 0000-0001-7880-7080
Shahzad M AliDepartment of Surgery, Mayo Clinic, Rochester, MN, USA.
Scott R KelleyDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Emilie DuchalaisDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Jasim Y AlabbadDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Eric J DozoisDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
David W LarsonDivision of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic · USJacksonville College · USMayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong-term oncologic outcomes after minimally invasive surgery (MIS) for rectal adenocarcinoma compared to open surgery continue to be debated. We aimed to review our high-volume single-institution outcomes in MIS rectal cancer surgery.

methodsA retrospective review of a prospectively collected database was completed of all consecutive adult patients with rectal adenocarcinoma treated from January 2005 through December 2011. Stage IV or recurrent disease was excluded. Demographics and operative and pathologic details were reviewed and reported. Primary endpoints include survival and recurrence.

resultsA total of 324 patients were included and median follow-up was 54 months (IQR = 37.0, 78.8). The mean age was 58.2 ± 14.1 years. Tumors were in the upper rectum in 111 patients, mid-rectum in 113 patients, and lower rectum in 100 patients. Stage III disease was most common (49.4%). Overall conversion to open procedure rate was 13.9%. The circumferential radial margin was positive in only 1 patient (0.3%) and the mean lymph node yield was 24.7 ± 17.2. Cancer recurred in 42 patients (13%), 10 (2.5%) patients developed local recurrence, 32 (9.8%) developed distant metastasis, and 2 (0.6%) patients had both. The 5-year overall survival for stage 0, 1, 2, and 3 disease is 96, 91, 80, and 77%, respectively (p = 0.015).

conclusionIn carefully selected rectal cancer patients treated with MIS, long-term outcomes of survival and recurrence appear to compare favorably to previously published series.

Indexed as

Neoplasm Recurrence, LocalAdenocarcinomaAdultAgedConversion to Open SurgeryCross-Sectional StudiesFemaleFollow-Up StudiesHumansLymph Node ExcisionLymph NodesMaleMargins of ExcisionMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingMinimally invasive surgeryMISProctectomyRectal adenocarcinomaRectal cancer

Identifiers

PMID29594912
OpenAlexW2795492104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.